BMY stock forecast, quote, news & analysis

Key Takeaways

• Bristol-Myers Squibb (BMY) surged approximately 12.5% over the last 30 days, rising from $54.00 on June 18 to $60.74 by July 17, 2026.
• The FDA's acceptance of the New Drug Application for mezigdomide in relapsed/refractory multiple myeloma served as a powerful near-term catalyst, driving a single-day gain of roughly 5.5%.
• Strong Q1 2026 results—with EPS of $1.58 beating consensus by $0.16 and revenue of $11.49 billion exceeding expectations—continued to underpin positive investor sentiment.
• Institutional accumulation remained robust, with major funds including Norges Bank, AQR Capital Management, and SEB Asset Management adding or initiating significant positions.
• Wall Street Zen upgraded BMY to "strong-buy" in late June, while the company's $0.63 quarterly dividend reaffirmed its commitment to shareholder returns.

Bristol-Myers Squibb (BMY) Company Overview and Market Position

Bristol-Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, dedicated to discovering, developing, and delivering innovative medicines for serious diseases. The company operates across multiple therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with a portfolio spanning both small-molecule drugs and biologics. Key products include Eliquis (cardiovascular), Opdivo (oncology), Breyanzi (cell therapy), Camzyos (cardiovascular), and Reblozyl (hematology). With a market capitalization of approximately $124 billion and a diversified pipeline featuring over 50 compounds, BMS remains a cornerstone holding in the pharmaceutical sector. Investors closely track the company for its ability to navigate upcoming patent expirations on Eliquis and Opdivo in 2028 while executing on new product launches.

Bristol-Myers Squibb (BMY) Stock Price Performance: Last 30 Days vs. Quarter

BMY shares have delivered a notable rally over the past 30 days, climbing from a closing price of $54.00 on June 18, 2026, to $60.74 by July 17, representing a gain of approximately 12.5%. The move was not linear—the stock dipped to the mid-$54 range in mid-June before a sharp inflection higher, punctuated by the mezigdomide FDA catalyst in July that propelled shares toward the $60 level. Over the broader quarter, BMY has demonstrated resilience, rising from the $55 area in late April through a series of higher lows and higher highs, supported by the Q1 earnings beat, pipeline momentum, and steady institutional inflows. The stock now trades comfortably above both its 50-day moving average of roughly $57 and its 200-day moving average near $58, signaling sustained bullish technical momentum.

What Drove BMY Stock Price in the Last 30 Days

The dominant catalyst behind BMY's 30-day surge was the FDA's acceptance of the New Drug Application for mezigdomide, a cereblon E3 ligase modulator (CELMoD) being developed in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. Supported by positive Phase 3 SUCCESSOR-2 data showing clinically meaningful improvements in progression-free survival, the regulatory milestone validated BMS's growing hematology pipeline and reinforced confidence in the company's post-patent-cliff growth narrative.

Several additional factors amplified the move. Wall Street Zen upgraded BMY to a "strong-buy" rating on June 27, injecting fresh bullish sentiment. Unusual call-options activity pointed to traders positioning for further upside. The company's quarterly dividend of $0.63 per share—declared June 17 and payable August 3—underscored management's confidence in cash flow generation. Meanwhile, continued institutional accumulation by firms such as Norges Bank, AQR Capital Management, Man Group, and SEB Asset Management provided a steady bid for the stock. Broader sector rotation into value-oriented healthcare names also contributed tailwinds, as investors gravitated toward BMY's combination of a 4.2% dividend yield and a relatively modest forward P/E ratio.

What Drove BMY Stock Performance Over the Last Quarter

BMY's quarterly strength traces back to its Q1 2026 earnings report on April 30, which exceeded consensus expectations across key metrics. The company posted EPS of $1.58 versus the $1.42 analyst estimate and generated $11.49 billion in revenue against a $10.93 billion forecast. Growth portfolio revenues rose 9% year-over-year to $6.2 billion, powered by Breyanzi (+53%), Camzyos (nearly doubling to ~$314 million), and Eliquis (+13%). Management reaffirmed full-year 2026 guidance of $6.05–$6.35 EPS and indicated the business was tracking toward the upper end of revenue and earnings ranges. The quarter also featured multiple regulatory milestones—including FDA acceptance of iberdomide with priority review and Breakthrough Therapy designation—and further pipeline progress that kept the long-term investment narrative intact. Against a backdrop of patent-expiration concerns, these developments helped shift market focus toward BMS's late-stage pipeline as a credible offset to upcoming revenue erosion.

Trending AI Robots

For traders seeking to complement fundamental analysis with data-driven automation, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron's platform hosts hundreds of AI-powered bots that trade thousands of tickers across equities, ETFs, and cryptocurrencies, but only the most relevant and highest-performing strategies surface in this trending section. Each bot operates with distinct strategies, timeframes, and risk profiles—ranging from short-term swing trading to longer-duration trend following—giving investors flexibility to align automated signals with their individual approach. Exploring the Trending AI Robots section can help traders identify momentum-based opportunities and diversify their decision-making toolkit.

BMY Stock Forecast Drivers: What Investors Should Watch Next

The most immediate catalyst on the horizon is BMY's Q2 2026 earnings report, scheduled for July 30, 2026, before the market opens. Analysts expect EPS of $1.61, up 10.3% year-over-year from $1.46, on continued growth portfolio momentum. Investors will scrutinize revenue contributions from newer drugs like Cobenfy, Camzyos, Breyanzi, and Sotyktu against potential erosion in legacy brands. Beyond earnings, key pipeline readouts expected in the second half of 2026—including pivotal data for Milvexian, Cobenfy in additional indications, and the iberdomide PDUFA date of August 17—could materially influence the stock's trajectory. Macroeconomic factors such as interest rate policy, drug pricing reform developments, and sector rotation patterns also warrant attention. While analyst consensus remains at "Hold" with an average price target near $61–$63, the wide range of targets ($40 to $75) reflects divergent views on BMS's ability to replace aging blockbuster revenues with new launches through 2030.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations